Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Effect of Cyclosporin A on the Growth of human Glioma Cell Lines

  • Pyen, Jhin-Soo (Department of Neurosurgery, Wonju College of Medicine, Yonsei University) ;
  • Kim, Soo-Kie (Department of Microbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Choi, Sun-Ju (Department of Microbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Park, Yoon-Sun (Department of Micorbiology, College of Medicine, Kwandong University) ;
  • Cho, Hyun-Chul (Department of Microbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Han, Young-Pyo (Department of Neurosurgery, Wonju College of Medicine, Yonsei University)
  • Published : 1997.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

Cyclosporin A, an potent immunosuppressant, has been known to be one of the modulators of drug resistance as well as a cytostatic drug. Despite many attempts to basic or clinical application of cyclosporin A, there are few reports on the inhibition of brain tumor cells. In the present experiment, the possibility of cyclosporin A as synergic adjuvant was investigated by MTT assay, $[^{3}H]$ thymidine uptake and through flowcytometric anaysis. Sole treatment of cyclosporin A on the CRT and CH235-MG glioma cell line revealed dose dependent cytotoxicity within a range of tested dose. Combined treatment of cyclosporin A with ACNU, BCNU and hydroxyurea on various glioma cancer cell line led to a significant synergistic cytotoxicity as well as inhibition of DNA synthesis with dose-dependency. In addition, cyclosporin A alone or combined treatment caused discernible changes of cell cycle in the tested cells. These data provide that cyclosporin A could potentiate the effect of nitrosourea compounds in vitro on human glioma cells.

Keywords

References

  1. Leukemia v.8 Cyclosporin A in the treatment of B-chronic Lymphocytic leukemia (B-CLL) Berguli,L.;Gregoretti,M.G.;Caligaris-Cappio,F.
  2. Semin. Oncol. v.13 Chemotherapy of brain tumors : physiological and pharmacokinetic considerations Blasberg,R.G.;Groothuis,D.R.
  3. Int. J. Cancer. v.58 Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein Botling,J.;Liminga,G.;Larsson,R.;Nygren,P.;Nilsson,K.
  4. Cancer. Res. v.47 Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity Carmichael,J.;deGraff,W.G.;Gazdar,A.F.;Minna,J.D.;Mitchel,J.B.
  5. Cancer v.52 Comparison of postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas Chang,C.H.;Horton,J.;Schoenfeld,D.;Slazer,O.
  6. J. Neurosurg. v.69 Flowcytometric determination of modal DNA population in relation to proliferative potential of human intracranial neoplasms Cho,K.G.;Nagashima,T.;Barnwell,S.;Hoshino,T.
  7. Eur. J. Pharmacol. v.26 no.289 Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist Gitter,B.D.;Waters,D.C.;Threlkeld,P.G.;Lovelace,A.M.:Mathumoto,K.;Bruns,R.F.
  8. J. Neurol. Neurosurg. Psychiarty. v.35 Malignant glioma of the brain stem : a clinicopathological analysis of 13 cases Golden,G.S.;Ghatak,N.R.;Hirano,A.;French,J.H.
  9. Neurosurgery v.33 Protein Kinase C inhibitor suppress cell growth in established and low-passage glioma cell lines. A comparison between stausporine and tamoxifen Goldon,H.B.;William,T.C.;Jean Guy,V.;Voon,W.Y.
  10. Curr. Opin. Lipidol. v.5 Chemotherapy of gliomas Kaye.A.H.;Laidlaw,J.D.
  11. Arch. Pharm. Res. v.19 In vitro chemosensitivity test of SK-302B on human colon carcinoma cell lines Kim,S.K.;Ahn,C.M.;Kim,T.U.;Choi,S.J.;Park,Y.S.;Shin,W.S.;Koh,C.M.
  12. Proc. Natl. Acad.Sci. USA. v.81 Cyclosporin A inhibits T cell growth factor gene expression at the level of m RNA transcription Kronke,M.;Leonard,W.J.;Depper,J.M.
  13. Neurosurgery v.36 no.1 Glial differentiation: A review with implications for new directions in neuro-oncology Linskey,M.E.;Gilbert,M.R.
  14. J. Kor. Cancer. Ass. v.21 Ministry of Health and Social Affairs, Five years report for cancer register program in the republic of Korea(1982.7.1-1989.6.30)
  15. Acta Neurochir. v.103 Chemotherapy for malignant gliomas of the brain: a review of ten-years experience Paoletti,P.;Butti,G.;Knerich,R.;Gaetani,P.;Assietti,R.
  16. A. J. Cancer Res. Clin. Oncol. v.120 Groeth inhibition of human gastrointestinal cancer cells by cyclosporin Piontek,M.;Porschen,R.
  17. Cancer v.68 Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma Roger,L.R.;Purvis,J.B.;Lederman,R.J.;Roswenbloom,S.A.
  18. Biochem. Pharmcol. v.48 vivo evidence for ATP-dependent and P-glycoprotein mediated transport of cyclosporin A at the blood-brain barrier Sakata,A.;Tamia,I.;Kawazu,K.;Daguchi,Y.;Ohnish,T.;Saheki,A.;Tsuji,A.
  19. Semin. Oncol. v.13 Principles of brain tumor chemotherapy Shapiro,W.R.;Shapiro,J.R.
  20. Cancer Res. v.52 Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells Soma,M.R.;Pagliarini,P.;Butti,G.;Paoletti,R.;Poletti,P.;Fumagalli,R.
  21. Proc. Am. Assoc. Cancer Res. v.35 A phase I study of cyclosporin A with Ara-C, mitoxantrone, etoposide in relapsed AML Thornton,D.E.;Villasmil,P.;Staubus,A.;Asif,M.
  22. N. Engl. J. Med. v.303 Randomized comparisons of radioteraphy and nitrosoureas for the treatment of malignant glioma after surgery Waker,M.D.;Green,S.B.;Byar,D.P.;Batzdorf,U.